Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.84 |
| ▸ | BACE1 | P56817 | 1/20 | 0.84 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | FPR2 | P25090 | 2/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.58 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374447 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL1141419 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL1141420 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL1377741 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL3089267 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL25330257 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL3089270 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL3969741 | 1.00 | ACHE (0.84) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL28194553 | 0.98 | ACHE (0.87) | ACHEBACE1PPARGFPR2GPR132 | |
| SCHEMBL25331522 | 0.95 | ACHE (0.77) | ACHEBACE1PPARGFPR2GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676460-A1 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING AND/OR PREVENTING HEMATOLOGIC DISORDERS AND RELATED DISEASES | Afimmune Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| CN-118714935-A | Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment | 阿马里纳药物爱尔兰有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240299328-A1 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING AND/OR PREVENTING HEMATOLOGIC DISORDERS AND RELATED DISEASES | AFIMMUNE LIMITED (IE) | 2024-09-12 | — | — | US | claimed |
| WO-2024184383-A1 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING AND/OR PREVENTING HEMATOLOGIC DISORDERS AND RELATED DISEASES | AFIMMUNE LIMITED (IE) | 2024-09-12 | — | — | WO | claimed |
| US-20240173285-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-05-30 | — | — | US | claimed |
| EP-4329742-A1 | COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-03-06 | — | — | EP | claimed |
| CN-116848260-A | Enzyme-based preparation of specific pro-inflammatory regressive mediators (SPMs) by docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) | 赢创运营有限公司 | 2023-10-03 | — | — | CN | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| US-10010492-B2 | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways | ELC MANAGEMENT LLC (US) | 2018-07-03 | — | — | US | claimed |
| US-20170319451-A1 | Methods And Compositions For Treating Skin To Resolve Inflammation And Screening For Actives That Stimulate Pro-Resolution Pathways | ELC MAN LLC (US) | 2017-11-09 | — | — | US | claimed |
| US-9682034-B2 | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways | ELC MANAGEMENT LLC (US) | 2017-06-20 | — | — | US | claimed |
| US-20130274327-A1 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID | THE UNIVERSITY OF TOKYO (JP) | 2013-10-17 | — | — | US | claimed |
| EP-2607358-A1 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID | The University of Tokyo (JP) | 2013-06-26 | — | — | EP | claimed |
| EP-4007500-B1 | PREPARATION COMPRISING OMEGA-3 FATTY ACID SALTS AND EXTRACTS OF GUM RESINS FROM BOSWELLIA SPECIES | EVONIK OPERATIONS GMBH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4676460-A1 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING AND/OR PREVENTING HEMATOLOGIC DISORDERS AND RELATED DISEASES | Afimmune Limited (IE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2013170006-A2 | OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS | SOLUTEX NA LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130274327-A1 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID | THE UNIVERSITY OF TOKYO (JP) | 2013-10-17 | — | — | US | disclosed |
| EP-2607358-A1 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID | The University of Tokyo (JP) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010492-B2 | Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways | ALOX15B, ALOX12, ALOX15 | ACHE 1026/4885BACE1 904/4885PPARG 286/4885 |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | ACHE 2692/4885BACE1 4477/4885PPARG 202/4885 |
| US-20130274327-A1 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID | PTGES3, ALOX5, ALOX15 | ACHE 2996/4885BACE1 2859/4885PPARG 166/4885 |
| US-20170319451-A1 | Methods And Compositions For Treating Skin To Resolve Inflammation And Screening For Actives That Stimulate Pro-Resolution Pathways | ALOX15B, ALOX12, ALOX15 | ACHE 1026/4885BACE1 904/4885PPARG 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.